ERNA Insider Trading

Insider Ownership Percentage: 35.43%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Eterna Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Eterna Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Eterna Therapeutics Share Price & Price History

Current Price: $1.79
Price Change: Price Increase of +0.05 (2.87%)
As of 04/26/2024 01:00 AM ET

This chart shows the closing price history over time for ERNA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Eterna Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/2/2022John D HalpernMajor ShareholderBuy335,920$3.28$1,101,817.60450,961View SEC Filing Icon  
12/2/2022Nicholas Jason SingerDirectorBuy283,286$3.28$929,178.08266,214View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Eterna Therapeutics (NASDAQ:ERNA)

70.55% of Eterna Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ERNA by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Eterna Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/13/2024Lake Street Advisors Group LLC520,996$0.93M0.1%N/A9.630%Search for SEC Filing on Google Icon
1/30/2024Sippican Capital Advisors54,050$97K0.1%+92.3%0.999%Search for SEC Filing on Google Icon
1/1/2024Vanguard Group Inc.24,898$54K0.0%+30.6%0.460%Search for SEC Filing on Google Icon
10/24/2023Sippican Capital Advisors28,100$61K0.1%+30.1%0.519%Search for SEC Filing on Google Icon
2/1/2023Cypress Point Wealth Management LLC94,375$0.30M0.5%N/A3.210%Search for SEC Filing on Google Icon
1/31/2023Naviter Wealth LLC79,621$0.39M0.1%N/A2.708%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Eterna Therapeutics logo
Eterna Therapeutics Inc. operates as a preclinical-stage, biopharmaceutical company. The company offers Synthetic mRNA, ToRNAdo mRNA Delivery, mRNA Gene Editing, and mRNA Cell Reprogramming. It also develops therapies and medicines using gene-editing proteins and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. The company was formerly known as Brooklyn ImmunoTherapeutics, Inc. and changed its name to Eterna Therapeutics Inc. in October 2022. Eterna Therapeutics Inc. is based in Cambridge, Massachusetts.
Read More on Eterna Therapeutics

Today's Range

Now: $1.79
Low: $1.58
High: $1.89

50 Day Range

MA: $2.06
Low: $1.53
High: $2.44

52 Week Range

Now: $1.79
Low: $0.84
High: $3.45

Volume

15,061 shs

Average Volume

9,137 shs

Market Capitalization

$9.68 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

4.16

Who are the company insiders with the largest holdings of Eterna Therapeutics?

Eterna Therapeutics' top insider investors include:
  1. John D Halpern (Major Shareholder)
  2. Nicholas Jason Singer (Director)
Learn More about top insider investors at Eterna Therapeutics.